The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: A prospective study

Journal of Nuclear Medicine

Volumn 52, Issue 10, 2011, Pages 1526-1534

  Groheux, David ^a,b   Giacchetti, Sylvie ^a   Espié, Marc ^a   Vercellino, Laetitia ^a   Hamy, Anne Sophie ^a   Delord, Marc ^b   Berenger, Nathalie ^a   Toubert, Marie Elisabeth ^a   Misset, Jean Louis ^a   Hindié, Elif ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

18F FDG; Bone scan; PET CT; Primary operable breast cancer; Stage II breast cancer; Stage IIIA breast cancer; Work up, initial staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; BONE TUMOR; BREAST TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053506695     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.093864     Document Type: Article

References (20)

1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2. 2011. Available at: http://www.nccn.org/professionals/physician-gls/f- guidelines.asp.
2. 18F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71:695-704.
3. Heusner TA, Kuemmel S, Umutlu L, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med. 2008;49:1215-1222.
4. 18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746-4751.
5. Aukema TS, Straver ME, Peeters MTFDV, et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer. 2010;46:3205-3210.
6. Segaert I, Mottaghy F, Ceyssens S, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 2010;16:617-624.
7. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
8. Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-1550.
9. Nakamoto Y, Cohade C, Tatsumi M, et al. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology. 2005;237:627-634. (Pubitemid 41507904)
10. Groheux D, Hindié E, Rubello D, et al. Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging. 2009;36:1539-1542.
11. Hindié E, Groheux D, Brenot-Rossi I, et al. The sentinel node procedure in breast cancer: nuclear medicine as the starting point. J Nucl Med. 2011;52:405-414.
12. Cooper KL, Harnan S, Meng Y, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2011;37:187-198.
13. 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435.
14. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109:417-426. (Pubitemid 351692058)
15. 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50:231-238.
16. 18F- fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009;115:5038-5047.
17. Morris PG, Lynch C, Feeney JN, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 2010;28:3154-3159.
18. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253-1258. (Pubitemid 41598715)
19. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am. 2007;45:669-676. (Pubitemid 47238392)
20. Dirisamer A, Halpern BS, Flöry D, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol. 2010;73:294-299.